Renal failure does not preclude cure in children receiving chemotherapy for Wilms tumor: A report from the national Wilms tumor study group

Pediatric Blood and Cancer

Volumn 50, Issue 2, 2008, Pages 242-245

  Feusner, James H ^a   Ritchey, Michael L ^b   Norkool, Pat A ^c   Takashima, Janice R ^c   Breslow, Norman E ^d   Green, Daniel M ^e,f  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b Pediatric Urology Associates   (United States)

^c USA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

^f UNIVERSITY AT BUFFALO   (United States)

Author keywords

Chemotherapy; Failure; Renal; Wilms

Indexed keywords

CISPLATIN; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; VINCRISTINE;

ADD ON THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; FEMALE; GRANULOCYTOPENIA; HUMAN; INFANT; KIDNEY FAILURE; MALE; NEPHROBLASTOMA; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CISPLATIN; DACTINOMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; INFANT; KIDNEY FAILURE; KIDNEY NEOPLASMS; MALE; TREATMENT OUTCOME; VINCRISTINE; WILMS TUMOR;

EID: 37549027243     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21229     Document Type: Article

References (20)

1. Breslow NE, Norris R, Norkool PA, et al. Characteristics and outcomes of children with the Wilms tumor-Aniridia syndrome: A report from the National Wilms Tumor Study Group. J Clin Oncol 2003;21:4579-4585.
2. Breslow NE, Takashima JR, Ritchey ML, et al. Renal failure in the Denys-Drash and Wilms' tumor-Aniridia syndromes. Cancer Res 2000;60:4030-4032.
3. Breslow NE, Collins AJ, Ritchey ML, et al. End stage renal disease in patients with Wilms tumor: Results from the National Wilms Tumor Study Group and the United States Renal Data System. J Urol 2005;174:1972-1975.
4. Ritchey ML, Green DM, Thomas PR, et al. Renal failure in Wilms' tumor patients: A report from the National Wilms' Tumor Study Group. Med Pediatr Oncol 1996;26:75-80.
5. Carlson L, Goren MP, Bush DA, et al. Toxicity, pharmacokinetics, and in vitro hemodialysis clearance of ifosfamide and metabolites in an anephric pediatric patient with Wilms' tumor. Cancer Chemother Pharmacol 1998;41:140-146.
6. Crews KR, Wimmer PS, Hudson JQ, et al. Pharmacokinetics of 2-chlorodeoxyadenosine in a child undergoing hemofiltration and hemodialysis for acute renal failure. J Pediatr Hematol Oncol 2002;24:677-680.
7. Dagher R, Kreissman S, Robertson KA, et al. High dose chemotherapy with autologous peripheral blood progenitor cell transplantation in an anephric child with multiply recurrent Wilms tumor. J Pediatr Hematol Oncol 1998;20:357-360.
8. English MW, Lowis SP, Peng B, et al. Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis. Br J Cancer 1996;73:776-780.
9. Koren G, Weitzman S, Klein J, et al. Comparison of carboplatin pharmacokinetics between an anephric child and two children with normal renal function. Med Pediatr Oncol 1993;21:368-372.
10. Veal GJ, English MW, Grundy RG, et al. Pharmacokinetically guided dosing of carboplatin in paediatric cancer patients with bilateral nephrectomy. Cancer Chemother Pharmacol 2004;54:295-300.
11. Iacono LC, Adams D, Homans AC, et al. Topotecan disposition in an anephric child. J Pediatr Hematol Oncol 2004;26:596-600.
12. Woo MH, Gregornik D, Shearer PD, et al. Pharmacokinetics of paclitaxel in an anephric patient. Cancer Chemother Pharmacol 1999;43:92-96.
13. Beckwith JB, Palmer NF. Histopathology and prognosis of Wilms tumors: Results from the First National Wilms' Tumor Study. Cancer 1978;41:1937-1948.
14. McCune JS, Adams D, Homans AC, et al. Cyclophosphamide disposition in an anephric child. Pediatr Blood Cancer 2006;46:99-104.
15. Prasad VK, Corlett SA, Abaasi K, et al. Ifosfamide enantiomers: Pharmacokinetics in children. Cancer Chemother Pharmacol 1994;34:447-449.
16. Boddy AV, Yule SM, Wyllie R, et al. Comparison of continuous infusion and bolus administration of ifosfamide in children. Eur J Cancer, 1995. 31A:786-790.
17. Newell, DR, Pearson AD, Balmanno K, et al. Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group. J Clin Oncol 1993;11:2314-2323.
18. Benjamin RS, Riggs CE Jr, Bachur NR. Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res 1977;37:1416-1420.
19. Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev 1995;21:33-64.
20. Powis G. Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs. Cancer Treat Rev 1982;9:85-124.